http://orcid.org/0000-0003-2533-5600
Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Giorgia Teresa Maniscalco, Cristina Scavone, Ornella Moreggia, Daniele Di Giulio Cesare, Maria Luisa Aiezza, Gaspare Guglielmi, Giuseppe Longo, Massimo Maiolo, Eliana Raiola, Giuseppe Russo & Annalisa Capuano. (2022) Flu vaccination in multiple sclerosis patients: a monocentric prospective vaccine-vigilance study. Expert Opinion on Drug Safety 21:7, pages 979-984.
Read now
Read now
Huah Shin Ng, Constanza Luzon Rosenbult & Helen Tremlett. (2020) Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. Expert Opinion on Drug Safety 19:9, pages 1069-1094.
Read now
Read now
Aurora Zanghì, Emanuele D’Amico & Francesco Patti. (2020) Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment. Expert Review of Neurotherapeutics 20:8, pages 771-782.
Read now
Read now
Cristina Scavone, Cristina Di Mauro, Simona Brusco, Michele Bertini, Gabriella di Mauro, Concetta Rafaniello, Liberata Sportiello, Francesco Rossi & Annalisa Capuano. (2019) Surveillance of adverse events following immunization related to human papillomavirus vaccines: 12 years of vaccinovigilance in Southern Italy. Expert Opinion on Drug Safety 18:5, pages 427-433.
Read now
Read now
Alberto Gajofatto & Marco Turatti. (2018) Investigational immunosuppressants in early-stage clinical trials for the treatment of multiple sclerosis. Expert Opinion on Investigational Drugs 27:3, pages 273-286.
Read now
Read now
Articles from other publishers (28)
Zeineb Zian, Abubakar Umar Anka, Hamisu Abdullahi, Emna Bouallegui, Shayan Maleknia & Gholamreza Azizi. 2024. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal
273
298
.
Zeqi Dai, Xue Wu, Chengyang Jing, Le Zhang, Nicola Robinson, Jun Tang & Xing Liao. (2023) Chinese herbal medicine for people with multiple sclerosis: Protocol for a systematic review and meta-analysis. European Journal of Integrative Medicine 58, pages 102220.
Crossref
Crossref
Mehdi Rezaee, Khosro Keshavarz, Sadegh Izadi, Abdosaleh Jafari & Ramin Ravangard. (2022) Economic burden of multiple sclerosis: a cross-sectional study in Iran. Health Economics Review 12:1.
Crossref
Crossref
Giorgia Teresa Maniscalco, Cristina Scavone, Annamaria Mascolo, Valentino Manzo, Elio Prestipino, Gaspare Guglielmi, Maria Luisa Aiezza, Santolo Cozzolino, Adele Bracco, Ornella Moreggia, Daniele Di Giulio Cesare, Antonio Rosario Ziello, Angela Falco, Marida Massa, Massimo Majolo, Eliana Raiola, Roberto Soprano, Giuseppe Russo, Giuseppe Longo, Vincenzo Andreone & Annalisa Capuano. (2022) The Safety Profile of COVID-19 Vaccines in Patients Diagnosed with Multiple Sclerosis: A Retrospective Observational Study. Journal of Clinical Medicine 11:22, pages 6855.
Crossref
Crossref
Francesca Washington & Dawn Langdon. (2021) Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review. Journal of Neurology 269:4, pages 1861-1872.
Crossref
Crossref
Emanuele D’Amico, Aurora Zanghì, Marzia Romeo, Eleonora Cocco, Giorgia Teresa Maniscalco, Vincenzo Brescia Morra, Damiano Paolicelli, Giovanna De Luca, Simonetta Galgani, Maria Pia Amato, Giuseppe Salemi, Matilde Inglese, Paolo Agostino Confalonieri, Giacomo Lus, Carlo Avolio, Antonio Gallo, Marika Vianello, Marco Onofrj, Massimo Filippi, Maria Trojano & Francesco Patti. (2021) Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. Neurotherapeutics 18:2, pages 905-919.
Crossref
Crossref
Andrew S. Ishizuka, Geoffrey M. Lynn & Christopher M. Jewell. 2021. Immunomodulatory Biomaterials. Immunomodulatory Biomaterials
139
173
.
Bruce A. C. Cree, Myla D. Goldman, John R. Corboy, Barry A. Singer, Edward J. Fox, Douglas L. Arnold, Corey Ford, Bianca Weinstock-Guttman, Amit Bar-Or, Susanne Mientus, Daniel Sienkiewicz, Ying Zhang, Rajesh Karan & Nadia Tenenbaum. (2021) Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology 78:1, pages 48.
Crossref
Crossref
Giorgia Maniscalco, Vincenzo Brescia Morra, Ciro Florio, Giacomo Lus, Gioacchino Tedeschi, Maddalena Cianfrani, Renato Docimo, Stefania Miniello, Felice Romano, Leonardo Sinisi, Daniele Spitaleri, Giuseppe Longo, Ugo Trama, Maria Triassi, Cristina Scavone & Annalisa Capuano. (2020) Preliminary Results of the FASM Study, an On-Going Italian Active Pharmacovigilance Project. Pharmaceuticals 13:12, pages 466.
Crossref
Crossref
Francisco Javier García-Fernández, Alba Estela García-Fernández, Eduardo Nava, Julian Solis Garcia del Pozo, Ichiro Ikuta, Joaquin Jordan & Maria F. Galindo. (2020) A bibliometric evaluation of the top 100 cited natalizumab articles. Journal of Neuroimmunology 349, pages 577379.
Crossref
Crossref
Despoina Florou, Maria Katsara, Jack Feehan, Efthimios Dardiotis & Vasso Apostolopoulos. (2020) Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab. Brain Sciences 10:10, pages 758.
Crossref
Crossref
Hesham R. El-Seedi, Shaden A.M. Khalifa, Aida Abd El-Wahed, Ruichang Gao, Zhiming Guo, Haroon Elrasheid Tahir, Chao Zhao, Ming Du, Mohamed A. Farag, Syed G. Musharraf & Ghulam Abbas. (2020) Honeybee products: An updated review of neurological actions. Trends in Food Science & Technology 101, pages 17-27.
Crossref
Crossref
Antonio Marangi, Gabriele Farina, Virginia Vicenzi, Stefano Forlivesi, Francesca Calabria, Fabio Marchioretto, Antonio Forgione, Francesca Rossi, Gianola Stenta, Marika Vianello, Alberto Gajofatto & Maria Donata Benedetti. (2020) Changing therapeutic strategies and persistence to disease-modifying treatments in a population of multiple sclerosis patients from Veneto region, Italy. Multiple Sclerosis and Related Disorders 41, pages 102004.
Crossref
Crossref
Lambros Messinis, Mary H Kosmidis, Grigorios Nasios, Spyridon Konitsiotis, Aikaterini Ntoskou, Christos Bakirtzis, Nikolaos Grigoriadis, Panayiotis Patrikelis, Elias Panagiotopoulos, Philippos Gourzis, Sonia Malefaki & Panagiotis Papathanasopoulos. (2020) Do Secondary Progressive Multiple Sclerosis patients benefit from Computer- based cognitive neurorehabilitation? A randomized sham controlled trial. Multiple Sclerosis and Related Disorders 39, pages 101932.
Crossref
Crossref
Cristina Scavone, Barbara Stelitano, Concetta Rafaniello, Francesco Rossi, Liberata Sportiello & Annalisa Capuano. (2019) Drugs-Induced Pathological Gambling: An Analysis of Italian Spontaneous Reporting System. Journal of Gambling Studies 36:1, pages 85-96.
Crossref
Crossref
Qian-Wen LI, Wen LEI, Cong CHEN & Wei GUO. (2020) Recent advances of long noncoding RNAs involved in the development of multiple sclerosis. Chinese Journal of Natural Medicines 18:1, pages 36-46.
Crossref
Crossref
Damiano Paolicelli, Alessia Manni, Antonio Iaffaldano & Maria Trojano. (2020) Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis. CNS Drugs 34:1, pages 65-92.
Crossref
Crossref
Karen K. Chung, Daniel Altmann, Frederik Barkhof, Katherine Miszkiel, Peter A. Brex, Jonathan O'Riordan, Michael Ebner, Ferran Prados, M. Jorge Cardoso, Tom Vercauteren, Sebastien Ourselin, Alan Thompson, Olga Ciccarelli & Declan T. Chard. (2019) A 30‐Year Clinical and Magnetic Resonance Imaging Observational Study of Multiple Sclerosis and Clinically Isolated Syndromes. Annals of Neurology 87:1, pages 63-74.
Crossref
Crossref
Cihat Uzunköprü & Yeşim Beckmann. (2019) Flammer syndrome in multiple sclerosis: diagnostics, prediction, and personalization of treatments. EPMA Journal 10:4, pages 437-444.
Crossref
Crossref
Maria de los Angeles Robinson-Agramonte, Carlos-Alberto Gonçalves, Roberto Farina de Almeida, Alina González Quevedo, Sandra Chow, Luis Velázquez Pérez, Amado Díaz de la Fé, Patricia Sesterheim & Diogo Onofre Gomes de Souza. (2019) Neuroinflammation and Neuromodulation in Neurological Diseases. Behavioral Sciences 9:9, pages 99.
Crossref
Crossref
Annamaria Mascolo, Rosanna Ruggiero, Maurizio Sessa, Cristina Scavone, Liberata Sportiello, Concetta Rafaniello, Francesco Rossi & Annalisa Capuano. (2019) Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System. Frontiers in Pharmacology 10.
Crossref
Crossref
Cristina Scavone, Gabriella di Mauro, Annamaria Mascolo, Liberato Berrino, Francesco Rossi & Annalisa Capuano. (2019) The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs. Frontiers in Pharmacology 10.
Crossref
Crossref
A. Connolly, V. Grandi, C.M. Stefanato, R. Palmer, A. Weir & S. Whittaker. (2018)
Primary cutaneous CD30
+
anaplastic large-cell lymphoma associated with fingolimod
. British Journal of Dermatology 179:6, pages 1400-1401.
Crossref
Crossref
Hao Chen, Xiaomeng Ma, Lei Si, Zhaoyu Chen, Xiuli Lin, Yuewu Yang & Xiaohong Chen. (2018) Traditional Chinese Medicine in Multiple Sclerosis: Theory and Practice. Current Pharmacology Reports 4:6, pages 436-446.
Crossref
Crossref
Beate Bittner, Wolfgang Richter & Johannes Schmidt. (2018) Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities. BioDrugs 32:5, pages 425-440.
Crossref
Crossref
Najam A. Sharif. (2018)
i
Drugs and
i
Devices Discovery Research: Preclinical Assays, Techniques, and Animal Model Studies for Ocular Hypotensives and Neuroprotectants
. Journal of Ocular Pharmacology and Therapeutics 34:1-2, pages 7-39.
Crossref
Crossref
Luanne M Metz & Wei-Qiao Liu. (2018) Effective treatment of progressive MS remains elusive. The Lancet 391:10127, pages 1239-1240.
Crossref
Crossref
NajamA Sharif. (2018) Glaucomatous optic neuropathy treatment options: the promise of novel therapeutics, techniques and tools to help preserve vision. Neural Regeneration Research 13:7, pages 1145.
Crossref
Crossref